Part of the MindAlert Series, sponsored by MetLife Foundation

View the Recorded
Version of This Event

Recent publications from workgroups convened by the National Institute on Aging and the Alzheimer’s Association focus on the role of biomarkers in disease detection, diagnosis and predicting clinical outcome for dementia due to Alzheimer’s disease. In this seminar we will review evidence of the relative value of genetic, imaging, and CSF (cerebrospinal fluid) markers in the early detection and diagnosis of Alzheimer’s disease. We will present evidence that neuropsychological assessment provides a central and non-interchangeable role in diagnosing Alzheimer’s disease, and that cognitive measures are among the best predictors of the initial symptomatic stages of an evolving dementia.  

Participants in this web seminar will be able to:

• Describe three classes of biomarkers for Alzheimer’s disease;
• Identify the relative value of biomarkers and neuropsychological measures to a diagnosis of Alzheimer’s disease; and,
• Understand the roles of biomarkers and neuropsychological measures in the prediction of disease progression to dementia.

Presenter:

Dr. Mark Bondi is a Professor of Psychiatry at the University of California San Diego and Director of the Neuropsychological Assessment Unit at the VA San Diego Healthcare System.  He is a Fellow of the American Psychological Association and the National Academy of Neuropsychology, and is Board Certified in Clinical Neuropsychology by the American Board of Professional Psychology. His research centers on the cognitive and brain changes of individuals at risk for dementia, he has published more than 130 articles and book chapters and he is the co-author of a new book on mild cognitive impairment and dementia.